The investigators aim at describing changes in renal glomerular and tubular function with
after the switch from TDF to TAF in HIV/HBV-coinfected patients with mild to moderate renal
dysfunction and to assess the virological efficacy of TAF on HBV infection.
The study will include HIV/HBV-coinfected participants of the Swiss HIV Cohort Study (SHCS)
who are under active care and have been on a stable, TDF-containing ART regimen for at least
6 months. Only patients with an estimated glomerular filtration rate (GFR) between 30 ml/min
and 90 ml/min will be included. All individuals who agree to participate will be switched
from a TDF-containing ART regimen to a TAF-containing triple ART regimen at week 0 and will
be followed for 48 weeks after the treatment change.